REpeated ASSEssment of SurvivorS in Intracerebral Hemorrhage Study

REpeated ASSEssment of SurvivorS in Intracerebral Hemorrhage Study

Go to 

Brief Summary:
The investigators propose to perform serial detailed cognitive, motor, behavioral, and blood collection follow-up using longitudinal structured telephone interviews of an anticipated 350 ICH survivors enrolled in Minimally Invasive Surgery Plus Alteplase for Intracerebral Hemorrhage Evacuation (MISTIE) III and ENRICH trials to identify specific cognitive and motor impairment and to perform RNA sequencing to evaluate for evidence of chronic inflammation. The investigators’ expected sample size in 2022 accounts for mortality attrition of 10%/year.

Intra Cerebral Hemorrhage ICH – Intracerebral Hemorrhage ICH Hemorrhage Stroke Clot (Blood); Brain Clot Blood Cognitive Decline Cognitive Impairment Survivorship Memory Impairment Motor Activity

Detailed Description:
The REASSESS study will conduct long-term cognitive, functional, and neuropsychiatric performance assessments to determine if evacuation of spontaneous intracerebral hemorrhage (ICH) reduces the risk of later cognitive decline in the ageing brain. This study will compare rates of cognitive decline under two treatment strategies for intracerebral hemorrhage: the use of minimally invasive surgery with two similar techniques as performed in the MISTIE III and ENRICH trials, and the current standard of care using data from controls in MISTIE III and ENRICH and comparative data from The Ethnic/Racial Variations of ICH (ERICH) study (U-01-NS067963) extended into the ERICH-Longitudinal study (R01-NS093870) which followed over 900 of ERICH cases with serial cognitive examinations.

Go to 

Layout table for study information

Study Type :

Estimated Enrollment :
350 participants

Observational Model:

Time Perspective:

Official Title:
The Repeated Assessment of Survivors in ICH (REASSESS ICH)

Estimated Study Start Date :
November 15, 2022

Estimated Primary Completion Date :
September 1, 2025

Estimated Study Completion Date :
December 31, 2027

Resource links provided by the National Library of Medicine

Go to 

Go to 

Primary Outcome Measures :

To determine if surgical clot reduction after ICH reduces the risk of progressive cognitive decline. [ Time Frame: 24 months ]

Primary outcome measure is the rate of cognitive decline which is based on a composite measure of global cognition using the National Institute on Aging Genetics Initiative for Late Onset Alzheimer Disease (NIA-LOAD) Battery.
Clot reduction measure will be obtained from semi-automated computerized volumetrics using the OsiriX software.
National Institute on Aging Genetics Initiative for Late Onset Alzheimer Disease (NIA-LOAD) Battery is a 7-measure cognitive testing battery to assess change in episodic, semantic, and working memory in community-dwelling older persons with broad ability levels.

Secondary Outcome Measures :

To determine if there is a long-term benefit in survival and functional outcome from minimally invasive surgery whether or not cognitive decline occurs [ Time Frame: 24 months ]

Survival and poor functional outcome (Modified Rankin Score (mRS) 4-6) will be calculated separately for cases with <=20 mL and >20 mL volume. We will use statistical modeling similar to Aim 1 to compute and calculate differences in hazard ratios for risk of mortality and poor outcome among <=20 mL and >20 mL survivors. We will assess interaction between cognitive decline and functional performance decline to evaluate whether these decline together.
Secondary outcome measures include the following: Modified Rankin Scale score (mRS), NIH Stroke Scale (NIHSS), Motor Assessment Scale (MAS), Western Aphasia Battery (WAB), Mini Mental Status Exam (MMSE), Barthel Index (BI), De Jong Gierveld Loneliness Scale, EuroQol 5 Dimension (EQ-5D), Activities of Daily Living (ADL) and fall history, Telephone Interview for Cognitive Status (TICS), Informant Questionnaire on Cognitive Decline in the Elderly (IQ-CODE) and Center for Epidemiological Studies Depression (CES-D).

Biospecimen Retention:   Samples With DNAComplete Blood Count, Ribonucleic Acid, Deoxyribonucleic Acid

Go to 

Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:  
Child, Adult, Older Adult

Sexes Eligible for Study:  

Accepts Healthy Volunteers:  

Sampling Method:  
Probability Sample

The study populations includes all surviving cases identified and recruited through the 5-year durations of the MISTIE III and ENRICH trials and with follow-up periods extending from 2013-2017 and 2016-2022, respectively.

Inclusion Criteria:

Participants in the study must be survivors enrolled in MISTIE III and ENRICH trials at end of each trial’s final follow-up (day 365 in MISTIE III and day 180 in ENRICH). Relatives of known survivors that are found to be deceased since the end of each trial will be interviewed to capture relevant data.

Exclusion Criteria:

Go to 

Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its identifier (NCT number): NCT05611918

Layout table for location information

Johns Hopkins Hospital

Baltimore, Maryland, United States, 21205

Johns Hopkins University
National Institute of Neurological Disorders and Stroke (NINDS)

Layout table for investigator information

Principal Investigator:
Wendy Ziai, MD
Johns Hopkins University

Go to 

Layout table for additonal information

Responsible Party:
Johns Hopkins University Identifier:

Other Study ID Numbers:
IRB00311985R01NS120557 ( U.S. NIH Grant/Contract )

First Posted:
November 10, 2022    Key Record Dates

Last Update Posted:
November 10, 2022

Last Verified:
October 2022

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD:

Plan Description:
NIH policy states grant award recipients must make unique resources readily available for research purposes to qualified individuals within the scientific community after publication. Drs. Ziai and Flaherty are committed to sharing resources, products, and data generated in this study. They are aware of and agree to abide by the principles for sharing research resources as described by NIH in “Principles and Guidelines for Recipients of NIH Research Grants and Contracts on Obtaining and Disseminating Biomedical Research Programs.”

Supporting Materials:
Study ProtocolStatistical Analysis Plan (SAP)Informed Consent Form (ICF)Clinical Study Report (CSR)

Time Frame:
9 months of database lock

Access Criteria:
We will share individual-participant-level data, in a de-identified format in compliance with the HIPAA privacy rule, which will make the data free of identifiers that would permit linkages to the research participants and free of content that would create unacceptable risk of subject identification.

Layout table for additional information

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Keywords provided by Johns Hopkins University:

Intracerebral hemorrhageStrokeCognitive Impairment

Additional relevant MeSH terms:

Layout table for MeSH terms

Cardiovascular DiseasesCerebral HemorrhageHemorrhageCognitive DysfunctionCerebrovascular DisordersBrain DiseasesCentral Nervous System Diseases
Nervous System DiseasesVascular DiseasesPathologic ProcessesCognition DisordersNeurocognitive DisordersMental DisordersIntracranial Hemorrhages

Source: View full study details on

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

November 11, 2022Comments OffCardiology | Cardiology Clinical Trials | Cardiology Studies | | Drug Trials Near Me | US National Library of Medicine